Axonal degeneration often leads to the death of neuronal cell bodies. Previous studies have demonstrated the crucial role of nicotinamide adenine dinucleotide (NAD) biosynthesis in axonal protection of motor neurons, but the role of nicotinamide mononucleotide adenylyltransferase 1 and NAD in optic nerve degeneration is unclear. Intravitreal injection of tumor necrosis factor (TNF) induces optic nerve degeneration and subsequent loss of retinal ganglion cells. We found that the levels of nicotinamide mononucleotide adenylyltransferase 1 mRNA and protein and of NAD were significantly decreased in the optic nerve after intravitreal injection of TNF in rats. The concomitant disorganization of microtubules with vacuoles and neurofilament accumulations in the axons were blocked by exogenous NAD treatment. Nicotinamide adenine dinucleotide also prevented TNF-induced axonal loss and delayed retinal ganglion cell loss 2 months after TNF injection. Microglia identified by immunohistochemistry were increased in the optic nerves after TNF injection; this increase was inhibited by NAD treatment. These results suggest that axonal nicotinamide mononucleotide adenylyltransferase 1 and NAD declines are associated with TNF-induced optic nerve axonal degeneration and that axonal protection of NAD may be related to its inhibitory effect on microglial activation.
INTRODUCTION
Axonal degeneration in the central nervous system occurs in many conditions, including multiple sclerosis, Alzheimer disease, and Parkinson disease, and often leads to the death of neuronal cell bodies (1, 2) . Axonal degeneration of retinal ganglion cells (RGCs) and apoptotic death of their cell bodies are also observed in glaucoma, for which reduction of intraocular pressure is known to slow progression of the disease. A pattern of localized retinal nerve-fiber layer defects in glaucoma patients indicates that axonal degeneration may precede RGC body death in this condition. The apoptotic cell death of neurons has been examined extensively. In contrast, the axonal degeneration pathway in the optic nerve has not been well documented despite evidence that the mechanisms of degeneration of neuronal cell bodies and their axons differ (2) . For example, overexpression of Bcl-2, an antiapoptotic gene, can prevent neuronal cell death but not axonal degeneration in a genetic mouse model of motor neuron disease (3) . BAX, a proapoptotic gene, is required for RGC body death but not for axonal degeneration in the DBA/2J mouse model of glaucoma (4) . In addition, experimental interventions in the apoptotic pathways for neuroprotection have not been successfully translated into wide clinical applications. Therefore, an understanding of the mechanism of axonal degeneration and intrinsic neuroprotective mechanisms may allow development of better preventive strategies for neurodegenerative diseases.
Nicotinamide adenine dinucleotide (NAD), a key intermediate in cellular energy homeostasis, has been suggested to play crucial roles in axonal degeneration of motor neurons. Recent studies in wallerian degeneration slow (Wld s ) mutant mice demonstrate that expression or elevated levels of nicotinamide mononucleotide adenylyltransferase 1 (Nmnat1), an enzyme that catalyzes the conversion of nicotinamide mononucleotide into NAD, protect axons of motor neurons from degeneration in vitro (5, 6) . A decrease in NAD levels in the spinal cord in experimental autoimmune encephalomyelitis was reported, and exogenous nicotinamide (NAm), an NAD precursor, was shown tohuman immunodeficiency virus-related encephalopathy (10Y12). In patients with glaucoma and human immunodeficiency virus<related optic neuropathy, TNF-mediated neurotoxicity in the eye has been linked to optic nerve degeneration (13Y16). Upregulation of TNF-receptor 1 has been reported in glaucomatous optic nerve heads (14) , and other studies have shown that TNF release by glial cells was induced upon exposure to simulated ischemia and elevated hydrostatic pressure, resulting in apoptotic RGC death (17) . More recently, TNF has been reported to play a central role in the pathophysiological events in experimental glaucoma (18) . We previously demonstrated that intravitreal injection of TNF induces progressive optic nerve degeneration with slow RGC body death (19) . The mode of degeneration seems to differ from that of the well-studied retinal neurotoxicity induced by glutamate or N-methyl-D-aspartate (NMDA), which involves early death of RGC bodies. These observations suggest that the TNF-induced neurodegeneration model may be useful for understanding the mechanisms of axonal degeneration of RGCs.
We first examined the effects of NAD in 2 different models of RGC and optic nerve degeneration in rats (i.e. TNF-induced neurodegeneration), which causes primary optic nerve degeneration with subsequent RGC body loss and NMDA-induced neurodegeneration that causes early death of the RGC body along with subsequent optic nerve degeneration. To understand the neuroprotective action of NAD in RGC axonal degeneration and the pathways of degeneration, we next evaluated the levels of Nmnat1 expression as well as NAD in the retina and optic nerve with axonal degeneration and the numbers of microglial cells in the TNF-induced optic neuropathy model.
MATERIALS AND METHODS

Animals
Experiments were performed on 50-to 55-day-old male Wistar rats; 254 rats and 39 rats were used for the TNF and NMDA studies, respectively; 4 naive rats were also used for immunohistochemistry. All studies were conducted according to the Association for Research in Vision and Ophthalmology statement for the Use of Animals in Ophthalmic and Vision Research. The animals lived in controlled conditions, with temperature at 23 T 1-C, humidity at 55% T 5%, and light from 6 AM to 6 PM.
Intravitreal Injections
Intravitreal injection of TNF (Sigma-Aldrich, St Louis, MO) or NMDA (Sigma-Aldrich) was performed as described previously (19, 20) . Briefly, rats were anesthetized by intramuscular injections of a mixture of ketamine-xylazine (10 and 4 mg/kg, respectively). A single 2-KL injection of 10 ng TNF or 20 nmol NMDA in 0.01 M phosphate-buffered saline (PBS; pH 7.40) was administered intravitreally into the right eye of an animal under a microscope to avoid lens injury. Phosphate-buffered saline was administered into the left eye as a control. The rats were killed 1 day, 1 or 2 weeks, or 2 months after the intravitreal injections by an intraperitoneal overdose of sodium pentobarbital, followed by enucleation of the eye. For NAD treatment, 0.2, 2, 20, or 200 nmol NAD (Sigma-Aldrich) in 2 KL of 0.01 M PBS or PBS alone was administered intravitreally 24 hours before or simultaneously with 10 ng TNF or 20 nmol NMDA injection.
Quantitative Real-Time Reverse-Transcription Polymerase Chain Reaction
The quantitative reverse-transcription polymerase chain reaction (PCR) with a real-time PCR system (Light-Cycler; Roche Diagnostics, Tokyo, Japan) was used as described previously, with a slight modification (20) . Briefly, 1 day or 2 weeks after intravitreal injection, retinas and optic nerves (4-mm length of optic nerve, removed right behind the globe) from a total of 108 rats were collected, and total RNA was isolated using acid guanidinium phenolYchloroform extraction (Promega Corporation, Madison, WI). For each sample, 4 optic nerve specimens were pooled, whereas each retina served as an individual sample. The expression of glyceraldehyde 3-phosphate dehydrogenase was used for normalization of variation between the levels of total cDNA template across different samples. The primers for Nmnat1 were 5 ¶-TGGCCAAGGACTATCTGA-3 ¶ (sense) and 5 ¶-TGAAGGACTCCAGCAAGT-3 ¶ (antisense), with a 402-bp amplicon (GenBank accession no. NM_001037556). The primers for glyceraldehyde 3-phosphate dehydrogenase were 5 ¶-CTGAGTATGTCGTGGAGTCTA-3 ¶ (sense) and 5 ¶-CTGCTTCACCACCTTCTTGAT-3 ¶ (antisense), with a 518-bp amplicon. Serial dilutions of the standard templates were also used for parallel amplifications. The threshold cycles were calculated with LightCycler software (version 5.32; Roche Diagnostics). Standard curves were plotted with threshold cycle-versus-log template quantities.
Western Blot Analysis
Rats (n = 57) were used for Western blot analysis as described previously (19) . Briefly, 1 day and 1 or 2 weeks after intravitreal injection, retinas and optic nerves (4-mm length) were collected, homogenized, and then centrifuged at 15,000 Â g for 15 minutes at 4-C. Optic nerve specimens (n = 3) were pooled for each sample; each retina served as an individual sample. Protein concentrations were determined using the Bio-Rad Protein Assay kit (Bio-Rad, Hercules, Calif ). Protein samples (5 Kg per lane for optic nerve samples; 10 Kg per lane for retinas) were subjected to sodium dodecyl sulfateYpolyacrylamide gel electrophoresis on 10% polyacrylamide gels and transferred to enhanced chemiluminescence membranes (Amersham Pharmacia Biotech, Piscataway, NJ). Membranes were blocked with Tris-buffered salineY0.1% Tween-20 containing 5% skim milk. Membranes were first reacted with anti-Nmnat1 antibody (1:200; Santa Cruz Biotechnology, Santa Cruz, Calif ) or antiYA-actin antibody (1:500; Sigma-Aldrich) in Tris-buffered saline containing 5% skim milk. The membranes were then subsequently exposed to peroxidase-labeled anti-goat immunoglobulin G antibody (Sigma-Aldrich) diluted 1:2000 or peroxidase-labeled anti-mouse immunoglobulin G antibody (Sigma-Aldrich) diluted 1:5000 in Tween-20 in Tris-buffered saline. Western blots were visualized with a chemiluminescence membrane detection system (ECL Plus Western Blotting Detection Reagents; Amersham Pharmacia Biotech).
Immunohistochemistry
For immunohistochemistry, 21 rats were used; 17 of these had received the intravitreal injection. Eyes collected 1 week after intravitreal injection or eyes from naive rats were fixed by immersion in 10% neutral buffered formalin for 24 hours, dehydrated, embedded in paraffin, and sectioned (4 Km thick) through the optic disk. Deparaffinized sections were incubated with 1% bovine serum and then reacted with primary antibodies against Nmnat1 (1:100; Santa Cruz Biotechnology), ionized calcium-binding adaptor molecule 1 (Iba1; a marker of microglial cells; 1:100; WAKO, Osaka, Japan), ED1 (CD68; a marker of macrophage/microglia; 1:50; AbD Serotec, Oxford, UK), glial fibrillary acidic protein (a marker of astrocytes; 1:100; DAKO Corporation, Carpinteria, Calif), neurofilament-L (a marker of neurons; 1:100; DAKO Corporation), or Thy-1 (a marker of RGC; 1:50; Santa Cruz Biotechnology) diluted in 1% bovine serum overnight at 4-C. Sections were then exposed to the following secondary antibodies: fluorescein isothiocyanate<labeled anti-rabbit antibody (1:100; Cappel, Aurora, OH), rhodaminelabeled anti-rabbit antibody (1:100; Cappel), fluorescein isothiocyanate<labeled anti-mouse antibody (1:100; Cappel), tetramethylrhodamine isothiocyanate-labeled anti-mouse antibody (1:100; Cappel), or fluorescein isothiocyanate<labeled anti-goat antibody (1:100; Cappel). For Iba1 and ED1 immunostaining, the samples were sectioned (8 Km thick) and counterstained with 4 ¶,6-diamidino-2-phenylindole (Vectashield with 4 ¶,6-diamidino-2-phenylindole; Vector Laboratories, Burlingame, Calif ). Negative controls were performed by replacing the primary antibody with PBS or serum. Specimens from the control groups were included and compared with those administered TNF or TNF + NAD.
Ionized calcium-binding adaptor molecule 1Ypositive cells with 4 ¶,6-diamidino-2-phenylindole in the optic nerve were counted in the images captured by a fluorescence confocal microscope (LSM510; Carl Zeiss, Germany). Two images of regions of lamina portion (52,900 Km 2 each) were obtained, and 3 sections were used for quantification in each eye (6 images for each eye). Data from 3 sections of each eye were averaged, and a minimum of 5 eyes for each experimental condition was examined.
High-Performance Liquid Chromatography
Assay of NAD was performed in a manner similar to that described previously with samples from 39 rats (6). Briefly, 1 and 2 weeks after intravitreal injection, optic nerves (4-mm length; 1 optic nerve preparation consisted of 3 optic nerves) and retinas (each retina served as an individual sample) were collected and homogenized in 150 KL (optic nerves) and 250 KL (retinas) of ice-cold buffer containing 0.3 M perchloric acid and 50 ng of acetaminophen as an internal standard. The homogenate was centrifuged at 15,000 Â g for 10 minutes at 4-C, and the protein content in the precipitates was determined using the Bio-Rad Protein Assay kit. The supernatants were neutralized to pH 6.4 to 7.0 by adding a 20% volume of ice-cold 3 M K 2 CO 3 , followed by precipitation on ice and centrifugation. The supernatants were passed through a 0.22-Km filter, and an aliquot (10 KL) was injected into a high-performance liquid chromatograph (510 Pump; Waters, Milford, MA) with an electrochemical detector (460 Detector; Waters) and a column (Cosmosil 5C18-AR Packed Column, 4.6 Â 150 mm; Nakalai Tesque, Kyoto, Japan). The mobile phase consisted of 0.1 M KH 2 PO 4 buffer containing 6 mM tetrabutylammonium phosphate, pH 5.5. All separations were performed isocratically at a flow rate of 0.9 mL/minute, and absorbance was monitored at 260 nm.
Axon Morphometry
Morphometric analysis of each optic nerve was performed as described previously with samples from 32 rats (19, 21) . Eyes were obtained from the animals 2 weeks after intravitreal injection. Two-millimeter segments of the optic nerves were obtained starting 1 mm behind the globe. These segments of optic nerve were fixed by immersion in Karnovsky solution for 24 hours at 4-C, processed, and embedded in acrylic resin. Cross-sections (1 Km thick) were cut beginning 1 mm from the globe and stained with a solution of 1% paraphenylene-diamine (Sigma-Aldrich) in absolute methanol (22) . For each section, images at the center and at each quadrant of the periphery (approximately 141.4 Km from the center) were acquired with a light microscope (Zeiss Axioskop; Carl Zeiss) with 1,250Â coupled digital camera (7.3 Three shot color; Diagnostic Instruments, Inc, Sterling Heights, MI) and associated Spot software (version 4.0.9; Diagnostic Instruments, Inc). The acquired images were quantified using the Aphelion image processing software (version 3.2; ADCIS SA and AAI, Inc, Hérouville Saint Clair, France). The number of axons was determined in 5 distinct areas of 2,713.5 Km 2 each (each quadrant of the periphery in addition to the center; total area of 13,567.5 Km 2 per eye) from each eye. The number of axons was averaged per eye and expressed as numbers per millimeter squared. A minimum of 4 eyes per experimental condition was used for analysis.
Retrograde Labeling of RGCs
Retrograde labeling of RGC was performed as described previously with samples from 11 rats (19) . Briefly, rats were anesthetized by intramuscular injections of a mixture of ketamine-xylazine. Labeling was performed by aspirating the cerebrum and placing a small piece of gel foam soaked in 6% solution of the neurotracer dye Fluorogold (Fluorochrome, Denver, CO) at the superior colliculus bilaterally 5 days before the intravitreal injection of TNF. Eyes obtained from animals 2 months after intravitreal injection were fixed and processed for flat-mount preparations. Tracer-labeled RGC counting was performed 1 mm from the edge of the optic disk under a fluorescence microscope (Zeiss) using a UV filter in 12 distinct areas of 273,700 Km 2 each (3 areas per each retinal quadrant). Distinguishable glial cells (bright, small, spindle-shaped cells) were excluded from the counting. Data from 12 areas from each eye were averaged for 1 eye, with a minimum of 5 eyes per experimental condition used.
Morphometry of Cells in RGC Layer
Morphometry of cells in the RGC layer (RGCL) was performed as described previously with samples from 21 rats (23). In brief, eyes obtained from animals 2 weeks after intravitreal injection of NMDA were fixed by immersion in 10% neutral buffered formalin for 1 hour. Retinas were separated and flat-mounted using a 1% gelatin solution with the RGCL facing upward. These preparations were stained with 1% cresyl violet. The numbers of cells in the RGCL were determined 1 mm from the edge of the optic disk in 8 distinct areas of 62,500 Km 2 each (2 areas per retinal quadrant). No attempt was made to distinguish the types of RGC and displaced amacrine cells, but morphologically distinguishable glial cells and vascular endothelial cells were excluded from the cell counts. Data from 8 areas from each eye were averaged for 1 eye; a minimum of 5 eyes per experimental condition was used for analysis. All quantification was performed in a masked manner.
Statistical Analysis
Data are presented as mean T SEM. Differences among groups were analyzed using 1-way analysis of variance, followed by Scheffe method or Mann-Whitney method. A probability value less than 0.05 was considered to represent a statistically significant difference.
RESULTS
Effects of NAD on TNF-and NMDA-Induced Neurodegeneration
We previously demonstrated myelin fragmentation and other degenerative changes involving large-caliber axons 2 weeks after TNF injection. Furthermore, after an approximately 30% loss of axons after 2 weeks, there was no further loss of axons at 1 or 2 months (19) . Consistent with our pre vious report and compared with PBS-treated eyes (Fig. 1A) , we again observed substantial degenerative changes in the axons after TNF injection (Fig. 1B) , whereas NAD-treated rats showed noticeably attenuated effects with better preserved nerve fibers (Fig. 1C) . Quantitative analysis confirmed the substantial protective effects of NAD (n = 6; Fig. 1D ). The numbers of axons after PBS, 10 ng TNF, 10 ng TNF + 0.2 nmol NAD, and 10 ng TNF + 2.0 nmol NAD injection were 223,024 T 12,914/mm 2 , 163,643 T 7,729/mm 2 , 211,887 T 15,508/mm 2 , and 222,168 T 9,453/mm 2 , respectively (Mann-Whitney test, p = 0.0472; TNF vs TNF + 0.2 nmol NAD, p = 0.0143; TNF vs TNF + 2.0 nmol NAD). The decrease in axon number was more prominent in fibers with diameters less than 1.5 Km; this decrease was completely precluded by 2.0 nmol NAD administration (Fig. 1E) . There was no significant difference in axon numbers among PBS-, TNF-, and TNF + NAD-administered eyes with axon diameters greater than 1.5 Km. Electron microscopy revealed substantial degenerated and degenerating axons with microtubule disorganization and neurofibrillary accumulation in the TNF-treated eyes (Fig. 1F) ; rats that received NAD showed preserved organization of microtubules (Fig. 1G ) and oligodendrocyte remyelination (not shown). Because we had previously observed a significant decrease in numbers of RGC 2 months after TNF injection (19), we examined the effect of NAD on numbers of RGC at that time point. In control retinas, the mean RGC density was 1,857 T 79 cells/mm 2 (n = 6; Figs. 2A, D), consistent with previous reports (19, 24) . Tumor necrosis factor induced a significant decrease in numbers of RGC at 2 months after injection (RGC density in TNF-treated eyes was 1,234 T 114 cells/mm 2 ; n = 5; p G 0.01 vs PBS-treated eyes;
Figs. 2B, D). The NAD-treated animals showed a significant amelioration of this loss (RGC density of TNF + NADtreated eyes was 1,835 T 141 cells/mm 2 ; n = 6; p G 0.05 vs TNF-treated eyes; Figs. 2C, D) .
In contrast to the temporal events of neurodegeneration after intravitreal injection of TNF, intravitreal NMDA injection causes early apoptotic death of both RGC and displaced and typical amacrine cells 12 to 24 hours after injection. Therefore, we examined the effect Copyright @ 2009 by the American Association of Neuropathologists, Inc. Unauthorized reproduction of this article is prohibited.
of NAD using whole-mounted flat preparations stained with cresyl violet to determine total cell numbers in the RGCL. As previously reported (23) , RGCL showed a significant decrease in cell numbers 2 weeks after NMDA injection (Figs. 3B, D) . Nicotinamide adenine dinucleotide did not have any effects on the loss of cells from the RGCL (Figs. 3C, D) or the loss of axons from the optic nerve (Fig. 3E) induced by NMDA. 
Nmnat1 and NAD in the Optic Nerve and the Retina
Previous studies demonstrated that Nmnat1 is present not only in the cell soma but also in the axons of motor neurons (25, 26) . To examine the role of NAD and its metabolic pathways further, we examined the localization of Nmnat1 in the optic nerve. Double-labeling immunohistochemical studies showed substantial colocalization of Nmnat1 and neurofilament in the optic nerve in normal rats (Fig. 4A) . In the retina, most Nmnat1-positive cells were colocalized with Thy-1Ypositive cells (Fig. 4B) . Hence, Nmnat1 is localized in both RGC bodies and their axons. By contrast, there was no colocalization of Nmnat1 and glial fibrillary acidic protein, a marker for astrocytes, in the optic nerve (data not shown) or retina (Fig. 4C) . Intravitreal injection of TNF induced a significant decrease in Nmnat1 mRNA levels in the optic nerve 1 day and 2 weeks after injection (Fig. 5A) . In contrast, there was no noticeable change in Nmnat1 mRNA levels in retinal samples at the same time points (Fig. 5B) . The products from completed real-time PCR runs were confirmed to be the specific amplification of Nmnat1 cDNA showing the corresponding specific band upon agarose gel electrophoresis with ethidium bromide staining and UV transillumination (Fig. 5C ). Western blot analysis showed a corresponding decrease in Nmnat1 protein levels in the optic nerve 1 and 2 weeks after TNF injection, although the change after 1 day was not significant (Fig. 5D) . Although Nmnat1 protein levels in the retina tended to be decreased after TNF injection compared with PBS injection, these changes were not significant (Fig. 5E ). High-performance liquid chromatograph analysis demonstrated that the NAD level in the optic nerve and the retina 1 week after PBS injection was 189.36 T 26.22 and 322.15 T 57.94 pmol/mg protein, respectively (Figs. 5F, G). There was a significant decrease in NAD levels in the optic nerve 1 and 2 weeks after TNF injection (Fig. 5F ) but not in the retina (Fig. 5G) .
Effects of NAD on Nmnat1 Expression
To explore the possibility that exogenous NAD can alter endogenous Nmnat1 expression, we examined the level of Nmnat1 mRNA 1 day after TNF injection. As expected, the decrease in expression of Nmnat1 mRNA in the optic nerve induced by TNF was not significantly altered by NAD treatment (Fig. 6A) . Moreover, the expression of Nmnat1 mRNA in the retina was not altered by TNF or TNF + NAD injection (Fig. 6B) .
Effects of NAD on TNF-Induced Microglial Activation
We and others have suggested that microglial activation may be involved in TNF-induced axonal degeneration (18, 19) . We therefore investigated whether NAD attenuates microglial activation in the optic nerve. Immunohistochemistry of Iba1 confirmed a noticeable increase in Iba1-immunopositive cells in the optic nerve 1 week after TNF injection (Fig. 7) . Ionized calcium-binding adaptor molecule 1 has been used as markers of activated microglia (27, 28) . We also observed substantial Iba1 immunostaining in PBS-treated eyes, consistent with the concept that Iba1 antibody can also recognize resting microglia in the brain (29) . The number of Iba1-immunopositive cells was significantly increased after TNF injection, and this increment was significantly inhibited by NAD administration (Figs. 7AYG) . Nicotinamide adenine dinucleotide alone, however, did not alter the number of immunopositive cells (Fig. 7G) . On the other hand, there were a few Iba1-immunopositive cells in the retina (approximately 1 mm from the optic nerve head) in PBS-treated eyes (Fig. 7H) and no noticeable change after TNF injection (Fig. 7I) . In contrast to Iba1 staining, there was minimal ED1 staining in PBS-treated eyes (Fig. 8A) . Substantial increase of ED1 immnunostaining was observed in TNF-treated eyes (Fig. 8B) , and an ameliorated effect was seen in the TNF + NAD-treated eyes (Fig. 8C) . In the TNF-treated eyes, most ED1 
DISCUSSION
The present study demonstrates that exogenous NAD prevented not only the loss of axons in the optic nerve but also the subsequent RGC loss after TNF injection. In contrast, NAD had no neuroprotective effect in NMDAinduced retinal and optic nerve degeneration. We demonstrated the presence of Nmnat1 in both the RGC bodies and their axons and that intravitreal TNF injection induced decreases in Nmnat1 expression and NAD levels in the optic nerve. Furthermore, NAD significantly suppressed the microglial activation induced by TNF. These results suggest that NAD and its associated biosynthetic pathways play a crucial role in TNF-induced optic nerve axonal degeneration.
We observed a substantial protective effect of exogenous NAD on TNF-induced axonal loss. This effect is consistent with other reports demonstrating the protective effect of exogenously applied NAD in axotomy-induced axonal degeneration in vitro (5, 6) . The protective effect of NAD was also confirmed by electron microscopy; that is, microtubule disorganization in the TNF-treated eyes was reduced by NAD treatment. Our observation that preventing axonal degeneration with NAD also leads to RGC body preservation is consistent with a recent study demonstrating that the Wld s mutation protects both axons and RGC bodies against glaucomatous changes in DBA/2J mice (30) . These findings differ from some reports demonstrating that although wallerian degeneration of axons in the Wld s mouse is delayed after optic nerve crush, the subsequent RGC death is not delayed (31) . This suggests that when retrograde axonal transport to RGC bodies is damaged, the Wld s protein does not prevent degeneration of RGC bodies. The difference between our model and the optic nerve crush model may be due to different degrees of axonal damage. This is consistent with the idea that the protection of neuronal cell bodies observed in several neurodegenerative diseases and injury models in which axons or significant axonal stumps remain may be due to endogenous neuroprotective mechanisms (32) .
To determine whether NAD has a direct protective effect on RGC bodies, we investigated NMDA-induced neurotoxicity in RGC bodies. Because intravitreal injection of NMDA causes RGC death from 12 hours after injection with the involvement of apoptosis (23) , axon loss may occur thereafter. Our present morphometric analysis showed no protective effect of NAD on RGC body loss or axon loss after NMDA injection. It has been reported, however, that NAm can exert a protective effect against ischemic neuronal damage (33). Thus, it remains unclear as to why some neuronal cells were preserved but others were not when treated with NAD. One hypothesis posits that the protective effect of NAD or Wld s protein may be observed in several types of axonal damage but that its effect on cell bodies may be dependent on the type of injury or on the neuronal cell type in individual tissues as well as on the conditions of axonal transport.
We postulate that a decline in Nmnat1 precedes the axonal degeneration because decreased levels of Nmnat1 mRNA and Nmnat1 protein in the optic nerve were observed from 1 day and 1 week after TNF injection, respectively, whereas significant axonal losses were only observed after 2 weeks. Because the Nmnat1 enzyme catalyzes the conversion of nicotinamide mononucleotide to NAD, the decrease in Nmnat1 may lead to a decrease in NAD; indeed, a significant decrease in NAD levels in the optic nerve after TNF injection was observed. This finding is consistent with the results of a previous study demonstrating a decline in NAD levels in the transected wallerian degenerating axons of dorsal root ganglia (6) . In addition, a progressive and significant decline in NAD was also shown in the cervical spinal cords of an experimental autoimmune encephalomyelitis model (7) .
Although Nmnat1 has been shown to be located in the nuclei of the cell body (34), our real-time PCR and Western blotting showed its presence in the optic nerve. Moreover, our immunolabeling study showed that Nmnat1 localizes in axon nerve fibers in the optic nerve as well as in RGC bodies. These findings are consistent with a previous demonstration that after the overexpression of Wld s , which consists of fulllength Nmnat1, it was located in the axons of dorsal root ganglia (26) . Interestingly, there was no significant difference in Nmnat1 mRNA and protein levels or of NAD levels in the retina between TNF-treated and PBS-treated eyes. There does seem to be a significant lag time involved in detecting loss of Nmnat1 mRNA and protein levels in the retina. As we confirmed that the main Nmnat1 immunoreactivity is RGC in the retina, the failure to detect Nmnat1 depletion in the retina up to 2 weeks after TNF injection may be associated with the finding that RGC body loss can only be observed 2 months after TNF injection. Another possibility is that the low proportion of RGC in the retinal cellular population, which is only 7% of total retinal cells, may make it difficult to detect the significant change in Nmnat1 expression in the retina (35) . Nonetheless, because TNF induces a primary axonal degenerative event in the optic nerve with subsequent retrograde RGC body involvement, it is reasonable to expect that the decrease in Nmnat1 and NAD levels in the optic nerve may be a major manifestation in the primary injured site.
It has been suggested that exogenously applied NAD can free Nmnat from its NAD synthesis function and allow more Nmnat to be involved in the protective function, thereby delaying degeneration (36) . We therefore examined whether exogenous NAD alters endogenous Nmnat levels in axons. Our real-time PCR experiment showed no significant effect of exogenous NAD on Nmnat1 mRNA in the optic nerve or the retina. Thus, it is more likely that exogenous NAD exerts its protective effect by mechanisms other than recruiting endogenous Nmnat1.
Previous studies demonstrated the activation of microglia in the optic nerve in an elevated intraocular pressure model and in a transection model (37Y39). Our present morphometric study of Iba1-positive cells clearly showed the activation of microglia in the optic nerve after TNF injection. The Iba1 immunostaining was substantially colocalized with ED1 immunostaining, which is increased after TNF injection. It has also been reported that cultured activated microglia release TNF, implying the existence of positive feedback regulation (40) . The microglial activation was significantly suppressed by NAD treatment. Recent studies have suggested that the ability to suppress microglial activation may lead to beneficial effects in several neuronal disorders and that the inhibition of microglial activation with minocycline or neurotrophic factor may have beneficial effects on RGC death in glaucoma and axotomy models (41Y45). Whether NAD regulates microglia activation via a direct or indirect mechanism is unclear, although previous in vitro study supports the direct effect of NAm, an NAD biosynthesis precursor, on lipopolysaccharide-activated microglia (7) . It is also interesting to note that NAm can inhibit the production of TNF and nuclear factor JB p65, thereby protecting cells against apoptosis (46, 47) . We previously demonstrated that most nuclear factor JB p65 immunostaining seemed to be present in ED1-and Iba1-positive cells in the optic nerve after TNF injection (19) , thus potentially implying that NAD may inhibit these cells along with TNF and nuclear factor JB p65 production in optic nerve degeneration.
In summary, our findings suggest that there is an early decrease in the expression of Nmnat1 in the optic nerve after TNF injection and that this decrease and sequential decline in NAD may be associated with TNF-induced axonal degeneration. Preventing axonal degeneration with NAD may lead to protective effects against delayed loss of RGC bodies. This remarkable NAD effect may derive from its inhibitory effect on microglial activation.
